The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.
A J
AJ
Johnson
Y-Y
YY
Yeh
L L
LL
Smith
A J
AJ
Wagner
J
J
Hessler
S
S
Gupta
J
J
Flynn
J
J
Jones
X
X
Zhang
R
R
Bannerji
M R
MR
Grever
J C
JC
Byrd
D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D003497:Cyclic N-Oxides; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D016207:Cytokines / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D007212:Indolizines; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011726:Pyridinium Compounds / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D059016:Tumor Microenvironment / Q000187:drug effects*
D019086:Bridged Bicyclo Compounds, Heterocyclic; D003497:Cyclic N-Oxides; D016207:Cytokines; D007212:Indolizines; D047428:Protein Kinase Inhibitors; D011726:Pyridinium Compounds; C553669:dinaciclib; D018844:Cyclin-Dependent Kinases